VEXAS syndrome and immune-mediated rheumatic diseases: overlaps in clinical features and mechanisms [0.03%]
VEXAS综合征与自身免疫性风湿病的临床特征及机制重叠点分析
Arvind Kaul,Adam Al-Hakim,Helen Lachmann et al.
Arvind Kaul et al.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome is a newly identified disorder caused by an acquired monogenic somatic UBA1 gene mutation, affecting nuclear and cytoplasmic ubiquitination. This mutation trigger...
Rebecca Grainger,Lisa K Stamp
Rebecca Grainger
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial [0.03%]
托法替布III期JUVE-RA研究的探索性分析：基线生物标志物与治疗反应之间的关联性研究
Venkatesh Krishnan,Stuart Y Keller,Christine Chew et al.
Venkatesh Krishnan et al.
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacod...
Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data [0.03%]
一项预测别嘌呤醇严重皮肤不良反应风险的预后模型的研制和验证：一项使用全科医疗、住院及死亡数据开展的回顾性新用户队列研究
Edoardo Cipolletta,Georgina Nakafero,Davide Rozza et al.
Edoardo Cipolletta et al.
Background: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous...
Biomarkers for juvenile idiopathic arthritis treatment response-have we identified them? [0.03%]
青少年特发性关节炎治疗反应的生物标志物-我们已经确定了吗？
Stephanie Ka Wong,Marinka Twilt
Stephanie Ka Wong
Dafna D Gladman
Dafna D Gladman
Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial [0.03%]
评估改良治疗方案（戈利木单抗+甲氨蝶呤+糖皮质激素）与常规治疗方案（甲氨蝶呤+糖皮质激素）对未经治早期银屑病关节炎疗效的差异：一项单中心、随机、双盲临床试验
Gabriele De Marco,Elizabeth M A Hensor,Philip S Helliwell et al.
Gabriele De Marco et al.
Background: The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corti...
From whole-brain metrics to circuit-specific precision: advancing fMRI biomarkers for TNF inhibitor response in rheumatoid arthritis [0.03%]
从全脑指标到特定电路的精准度：推进风湿性关节炎肿瘤坏死因子抑制剂反应的fMRI生物标志物的发展
Aikeremujiang Muheremu,Kan Jiang
Aikeremujiang Muheremu
From whole-brain metrics to circuitspecific precision: advancing fMRI biomarkers for TNF inhibitor response in rheumatoid arthritis - Authors' reply [0.03%]
从全脑指标到特定电路的精准性：改善肿瘤坏死因子抑制剂反应的类风湿关节炎的功能磁共振生物标志物——作者回信
Andreas Hess,Koray Tascilar,Georg Schett et al.
Andreas Hess et al.
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights [0.03%]
纳伦德拉·库马尔·巴格里：印度儿科风湿病学的新高度
Heather Van Epps
Heather Van Epps